| PTLE 0.282 51.53% | SOXS 3.65 11.56% | MSPR 0.664 27.57% | SCNX 0.8182 15.35% | NVDA 198.69 -3.96% | SQQQ 13.79 6.16% | ORIS 0.1603 -0.12% | BYND 1.33 -4.32% | PFE 24.3 -1.46% | HTZ 6.73 36.23% | PLTR 190.74 -7.94% | TSLL 20.34 -10.16% | ETHA 24.28 -10.37% | ASST 1.25 -1.57% | IBIT 57.18 -5.53% | GRAB 5.785 -4.70% | INTC 37.03 -6.25% | PLUG 2.52 -8.36% | ONDS 5.96 -3.09% | OPEN 6.92 -8.83% | CHR 0.136 8.11% | FGL 0.5165 26.94% | DNN 2.74 -6.00% | TSLA 444.26 -5.15% | WTO 0.0497 -6.23% | CAPT 0.6615 31.77% | NFE 1.35 14.41% | SOXL 42.8 -11.90% | BITF 3.84 -6.57% | ETHD 5.26 20.92% | T 24.44 -0.37% | EPWK 0.0748 3.60% | F 12.79 -1.69% | SPY 675.24 -1.19% | SOFI 29.37 -4.11% | KVUE 15.97 -1.05% | ACHR 9.56 -8.25% | CIFR 22.51 -1.10% | QQQ 619.25 -2.03% | HIMS 42.79 -3.60% | GPUS 0.3494 -7.03% | TQQQ 111.08 -6.12% | LQD 110.68 0.14% | BTBT 3.18 -7.02% | AAL 12.65 -5.17% | TZA 8.21 5.26% | BURU 0.29 -7.91% | NCLH 18.79 -15.28% | RGTI 35.18 -10.07% | BTG 4 -5.77%

Lazard Ltd (NYSE:LAZ) Earnings Preview and Financial Health Analysis

Lazard Ltd (NYSE:LAZ), a leading financial advisory and asset management firm, is gearing up to release its quarterly earnings on October 23, 2025. The firm, known for its expertise in mergers and acquisitions, restructuring, and capital raising, competes with financial giants such as Goldman Sachs and Morgan Stanley. Analysts are estimating an earnings per share (EPS) of $0.44 and revenue of $726.25 million. The consensus EPS estimate has seen a downward revision of 1.8% over the past 30 days, potentially impacting investor sentiment.

The market's reaction to earnings estimate revisions is significant, as empirical studies suggest. Should Lazard's actual earnings surpass expectations, the stock might witness an upward trend. On the other hand, if the earnings disappoint, the stock could face a decline. The insights shared during the earnings call will be crucial for investors to gauge the sustainability of any immediate price changes.

Examining Lazard's financial metrics reveals its market valuation. The firm boasts a price-to-earnings (P/E) ratio of 15.67, a price-to-sales ratio of 1.52, and an enterprise value to sales ratio of 1.37. These figures indicate how the market values Lazard's earnings and sales.

The company's financial health is underscored by a debt-to-equity ratio of 0.70 and a current ratio of 1.89. These ratios suggest a balanced approach to financing its assets and the ability to cover short-term liabilities with short-term assets, respectively. As Lazard approaches its earnings release, these metrics offer a comprehensive view of its financial standing.

Published on: October 23, 2025